Plexium

Targeted protein degradation (TPD) is a way to inhibit or modulate the function of disease-causing proteins that aren’t druggable using conven­tional small molecules. Plexium is using a proprietary high-throughput cell screening technology to explore a variety of potential next-generation approaches to TPD, from monovalent protein degraders to molecular glues to novel E3 ligases. With partners, and on its own, the company is developing TPD drugs to fight cancer, central nervous system diseases, and other conditions.